GOALS: The purpose of this study was to evaluate the efficacy of oral cryotherapy to prevent high-dose melphalan-induced stomatitis. PATIENTS AND METHODS: Eighteen consecutive recipients of allogeneic hematopoietic stem cell transplant conditioned with high-dose melphalan (140 mg/m2) in combination with fludarabine alone or with fludarabine and additional chemotherapy or radiation were enrolled. The severity of stomatitis was graded according to the National Cancer Institute Common Toxicity Criteria. Patients were kept on oral cryotherapy using ice chips and ice-cold water shortly before, during, and for additional 90 min after completion of melphalan administration. RESULTS: Only two of 18 patients (11.1%) developed grade 2 or 3 stomatitis while six of seven patients in the historical control developed it (85.7%; P=0.001). CONCLUSION: These results suggested that oral cryotherapy could effectively prevent stomatitis caused by high-dose melphalan, and we recommend that it should be incorporated into the conditioning regimen with high-dose melphalan.
GOALS: The purpose of this study was to evaluate the efficacy of oral cryotherapy to prevent high-dose melphalan-induced stomatitis. PATIENTS AND METHODS: Eighteen consecutive recipients of allogeneic hematopoietic stem cell transplant conditioned with high-dose melphalan (140 mg/m2) in combination with fludarabine alone or with fludarabine and additional chemotherapy or radiation were enrolled. The severity of stomatitis was graded according to the National Cancer Institute Common Toxicity Criteria. Patients were kept on oral cryotherapy using ice chips and ice-cold water shortly before, during, and for additional 90 min after completion of melphalan administration. RESULTS: Only two of 18 patients (11.1%) developed grade 2 or 3 stomatitis while six of seven patients in the historical control developed it (85.7%; P=0.001). CONCLUSION: These results suggested that oral cryotherapy could effectively prevent stomatitis caused by high-dose melphalan, and we recommend that it should be incorporated into the conditioning regimen with high-dose melphalan.
Authors: S Giralt; A Aleman; A Anagnostopoulos; D Weber; I Khouri; P Anderlini; J Molldrem; N T Ueno; M Donato; M Korbling; J Gajewski; R Alexanian; R Champlin Journal: Bone Marrow Transplant Date: 2002-09 Impact factor: 5.483
Authors: S M Devine; R Sanborn; E Jessop; W Stock; M Huml; D Peace; A Wickrema; M Yassine; K Amin; D Thomason; Y H Chen; H Devine; M Maningo; K van Besien Journal: Bone Marrow Transplant Date: 2001-09 Impact factor: 5.483
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Nicolaus Kröger; Rainer Schwerdtfeger; Michael Kiehl; Herbert Gottfried Sayer; Helmut Renges; Tatjana Zabelina; Boris Fehse; Florian Tögel; Georg Wittkowsky; Rolf Kuse; Axel Rolf Zander Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: L K Rocke; C L Loprinzi; J K Lee; S J Kunselman; R K Iverson; G Finck; D Lifsey; K C Glaw; B A Stevens; A K Hatfield Journal: Cancer Date: 1993-10-01 Impact factor: 6.860
Authors: Nicolaus Kröger; Herbert Gottfried Sayer; Rainer Schwerdtfeger; Michael Kiehl; Arnon Nagler; Helmut Renges; Tatjana Zabelina; Boris Fehse; Francis Ayuk; Georg Wittkowsky; Norbert Schmitz; Axel Rolf Zander Journal: Blood Date: 2002-08-08 Impact factor: 22.113
Authors: D J Mahood; A M Dose; C L Loprinzi; M H Veeder; L M Athmann; T M Therneau; J M Sorensen; D K Gainey; J A Mailliard; N L Gusa Journal: J Clin Oncol Date: 1991-03 Impact factor: 44.544
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Douglas E Peterson; Kerstin Ohrn; Joanne Bowen; Monica Fliedner; Judith Lees; Charles Loprinzi; Takehiko Mori; Anthony Osaguona; Dianna S Weikel; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2012-09-21 Impact factor: 3.603
Authors: Axel Grothey; Alex A Adjei; Steve R Alberts; Edith A Perez; Kurt A Jaeckle; Charles L Loprinzi; Daniel J Sargent; Jeff A Sloan; Jan C Buckner Journal: Semin Oncol Date: 2008-10 Impact factor: 4.929